EUCTR2016-004566-26-SI进行中（未招募）1 期
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis - AURORA
Tobira Therapeutics, Inc., a subsidiary of Allergan plc0 个研究点目标入组 1,778 人开始时间: 2018年3月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,778
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects aged between 18-75 years
- •2. Ability to understand and sign a written informed consent form (ICF)
- •3. Histological evidence of NASH based on central reading of the biopsy slides
- •4. Histological evidence of Stage 2 or 3 liver fibrosis per the NASH CRN System based on central reading of the biopsy slides
- •5. Females of childbearing potential and males participating in the study must agree to use at least 2 approved methods of contraception throughout the duration of the study and for 30 days after stopping study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1800
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1. Inability to undergo a liver biopsy
- •2. Hepatitis B surface antigen (HBsAg) positive
- •3. Hepatitis C antibody (HCVAb) positive
- •4. Human immunodeficiency virus (HIV)-1 or HIV-2 infection
- •5. Prior or planned liver transplantation
- •6. Other known causes of chronic liver disease
- •7. History or presence of cirrhosis and/or hepatic decompensation including ascites, hepatic encephalopathy or variceal bleeding
- •8. Alcohol consumption greater than 21 units/week for males or 14 units/week for females
- •9. AST > 5 × upper limit of normal (ULN) at Screening
- •10. ALT > 5 × ULN at Screening
- •11. HbA1c > 9% at Screening
- •12. Serum albumin < 3.5 g/dL
- •13. Estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) equation
- •14. Platelet count < 100,000/mm3
- •15. Total bilirubin > 1.3 mg/dL (subjects with hyperbilirubinemia associated with documented Gilbert’s syndrome may be eligible upon review by the medical monitor)
- •16. International normalized ratio (INR) > 1.3
- •17. Model of end stage liver disease (MELD) score > 12
- •18. Weight reduction through bariatric surgery in the past 5 years or planned during the conduct of the study (including gastric banding and sleeve surgery)
- •19. Known history of hepatocellular carcinoma (HCC) at any time, history of malignancy within the past 5 years or ongoing malignancy other than: basal cell carcinoma, resected noninvasive cutaneous squamous cell carcinoma, or treated stage II or lower colorectal or breast cancer in remission for = 2 years and with documented low risk of recurrence (including but not limited to Oncotype DX 12 gene recurrence score <30 for stage II or lower colon cancer; early-stage, estrogen-receptor-positive, HER2-negative breast cancers that have not spread to the lymph nodes; Oncotype DX 21 gene recurrence score <18 for earlystage invasive breast cancer; or Oncotype DX ductal carcinoma in situ [DCIS] 12 gene recurrence score <39 for noninvasive breast cancer)
- •20. Active, serious infections that require parenteral therapy (antibiotic or antifungal) within 30 days prior to Screening Visit
- •21. Clinically significant cardiovascular or cerebrovascular disease within the past 3 months
- •22. Females who are pregnant or breastfeeding
- •23. Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic agents and immunomodulating agents (such as systemic corticosteroids, interleukins and interferons)
- •24. Receiving a glucagon-like peptide 1 (GLP-1) receptor agonist, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, or a thiazolidinedione (TZD) for less than 6 months of stable therapy prior to the liver biopsy at Screening
- •25. Receiving ongoing therapy with any disallowed medication between Screening and Baseline visits.
- •26. Allergy to the study drug or its components
- •27. Receiving any investigational products within 30 days prior to Screening or anticipated use during the trial
- •28. Receiving any investigational product being evaluated for the treatment of liver fibrosis or NASH in the 6 months prior to the Screening liver biopsy (subjects documented to be assigned to placebo in such trials may be eligible immediately following completion of their participation in the previous trial)
- •29. Participation in any other clinical trial at Screening without approval from the sponsor
- •30. Any other clinically significant disorders or prior therapy that, in the opinion of
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents who are Hospitalized due to Serious Influenza.MedDRA version: 14.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsInfluenzaEUCTR2009-012367-34-BGBioCryst Pharmaceuticals, Inc.600
招募中
1 期
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004294-14-NOCelgene International II Sàrl485
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Active Crohn's Diseasemoderately to severely active Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-004614-18-HUEli Lilly and Company1,150
进行中（未招募）
1 期
The study of an investigational drug, Cenicriviroc, for the treatment of liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH).iver fibrosis in Subjects with Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-004566-26-BETobira Therapeutics Inc., a subsidiary of Allergan plc2,000
进行中（未招募）
1 期
A Phase 3 Study in Moderate to Severe Chronic Psoriasis PatientsMedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858Plaque PsoriasisEUCTR2014-003492-36-BGCB Biopharma, SPR561